drugset / Trial / NCT00330317

Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer

NCT00330317

Phase 3 Completed 300 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to assess the safety and efficacy of neoadjuvant hormone therapy with letrozole in postmenopausal women with estrogen- and/or progesterone-receptor positive primary breast cancer on tumour regression to permit breast conserving surgery.

Timeline

Start
2006-02
Primary completion
2010-03
Completion
2010-11-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Letrozole Other / unclassified 2.5 mg Oral